Literature DB >> 23273719

Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Joshua P Loh1, Lakshmana K Pendyala, Hironori Kitabata, Rebecca Torguson, Fang Chen, Kenneth M Kent, Lowell F Satler, William O Suddath, Augusto D Pichard, Ron Waksman.   

Abstract

Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) commonly receive a loading dose of either clopidogrel or prasugrel, in addition to aspirin. The present study aimed to assess the safety of reloading prasugrel in patients who had initially received a loading dose of clopidogrel compared to prasugrel loading alone. The study included a cohort of 606 consecutive patients with acute coronary syndrome who had received a 60-mg loading dose of prasugrel before PCI. These patients were then categorized into clopidogrel preloading (300 or 600 mg) followed by prasugrel reloading (CP-load group, n = 90) and prasugrel loading only (P-load group, n = 516). Both groups received a 10-mg maintenance dose of prasugrel after PCI. The primary end point was in-hospital Thrombolysis In Myocardial Infarction-defined major bleeding. The secondary end points were other in-hospital bleeding complications and major cardiovascular events. Patients in the CP-load group compared to the P-load group were younger, with lower rates of cardiovascular risk factors. Significantly more patients in the CP-load group presented with biomarker-positive myocardial infarction (80.0% vs 30.6%, p ≤0.001) and cardiogenic shock (5.6% vs 1.4%, p = 0.022). No significant differences (p = NS) were seen in Thrombolysis In Myocardial Infarction major bleeding (2.6% vs 2.8%), Thrombolysis In Myocardial Infarction major or minor bleeding (12.2% vs 7.0%), the need for blood transfusion (2.6% vs 2.1%), and vascular complications (1.3% vs 2.0%) between groups. The CP-load group experienced more in-hospital major adverse cardiac events (5.6% vs 1.6%, p = 0.031), urgent coronary artery bypass grafting (3.3% vs 0.2%, p = 0.011), and longer hospital and intensive care unit stays. In conclusion, preloading with clopidogrel should not be prohibitive to reloading with prasugrel in patients presenting with acute coronary syndrome and undergoing PCI with respect to bleeding and vascular complications.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23273719     DOI: 10.1016/j.amjcard.2012.11.058

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

Review 2.  The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.

Authors:  Jaya Chandrasekhar; Benjamin Hibbert; Michael Froeschl; Derek So; Roxana Mehran; Michel Le May
Journal:  Eur J Clin Pharmacol       Date:  2015-10-09       Impact factor: 2.953

3.  Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.

Authors:  Giuseppe De Luca; Monica Verdoia; Alon Schaffer; Harry Suryapranata; Guido Parodi; David Antoniucci; Paolo Marino
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

4.  Switching from clopidogrel to prasugrel in patients having coronary stent implantation.

Authors:  Guido Parodi; Giuseppe De Luca; Benedetta Bellandi; Vincenzo Comito; Renato Valenti; Rossella Marcucci; Nazario Carrabba; Angela Migliorini; R N Erica Ramazzotti; Gian Franco Gensini; Rosanna Abbate; David Antoniucci
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

5.  Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.

Authors:  Manuel Almendro-Delia; Emilia Blanco Ponce; Rocío Gomez-Domínguez; Carlos Gonzalez-Matos; Manuel Lobo-Gonzalez; Auxiliadora Caballero-Garcia; Rafael Hidalgo-Urbano; Maria Jose Cruz-Fernandez; Juan C Garcia-Rubira
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

6.  Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021.

Authors:  José Carlos Nicolau; Gilson Soares Feitosa Filho; João Luiz Petriz; Remo Holanda de Mendonça Furtado; Dalton Bertolim Précoma; Walmor Lemke; Renato Delascio Lopes; Ari Timerman; José A Marin Neto; Luiz Bezerra Neto; Bruno Ferraz de Oliveira Gomes; Eduardo Cavalcanti Lapa Santos; Leopoldo Soares Piegas; Alexandre de Matos Soeiro; Alexandre Jorge de Andrade Negri; Andre Franci; Brivaldo Markman Filho; Bruno Mendonça Baccaro; Carlos Eduardo Lucena Montenegro; Carlos Eduardo Rochitte; Carlos José Dornas Gonçalves Barbosa; Cláudio Marcelo Bittencourt das Virgens; Edson Stefanini; Euler Roberto Fernandes Manenti; Felipe Gallego Lima; Francisco das Chagas Monteiro Júnior; Harry Correa Filho; Henrique Patrus Mundim Pena; Ibraim Masciarelli Francisco Pinto; João Luiz de Alencar Araripe Falcão; Joberto Pinheiro Sena; José Maria Peixoto; Juliana Ascenção de Souza; Leonardo Sara da Silva; Lilia Nigro Maia; Louis Nakayama Ohe; Luciano Moreira Baracioli; Luís Alberto de Oliveira Dallan; Luis Augusto Palma Dallan; Luiz Alberto Piva E Mattos; Luiz Carlos Bodanese; Luiz Eduardo Fonteles Ritt; Manoel Fernandes Canesin; Marcelo Bueno da Silva Rivas; Marcelo Franken; Marcos José Gomes Magalhães; Múcio Tavares de Oliveira Júnior; Nivaldo Menezes Filgueiras Filho; Oscar Pereira Dutra; Otávio Rizzi Coelho; Paulo Ernesto Leães; Paulo Roberto Ferreira Rossi; Paulo Rogério Soares; Pedro Alves Lemos Neto; Pedro Silvio Farsky; Rafael Rebêlo C Cavalcanti; Renato Jorge Alves; Renato Abdala Karam Kalil; Roberto Esporcatte; Roberto Luiz Marino; Roberto Rocha Corrêa Veiga Giraldez; Romeu Sérgio Meneghelo; Ronaldo de Souza Leão Lima; Rui Fernando Ramos; Sandra Nivea Dos Reis Saraiva Falcão; Talia Falcão Dalçóquio; Viviana de Mello Guzzo Lemke; William Azem Chalela; Wilson Mathias Júnior
Journal:  Arq Bras Cardiol       Date:  2021-07       Impact factor: 2.667

7.  High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.

Authors:  Tobias Geisler; Jean Booth; Elli Tavlaki; Athanasios Karathanos; Karin Müller; Michal Droppa; Meinrad Gawaz; Monica Yanez-Lopez; Simon J Davidson; Rod H Stables; Winston Banya; Azfar Zaman; Marcus Flather; Miles Dalby
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

8.  Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE).

Authors:  Leonardo De Luca; Furio Colivicchi; Michele Massimo Gulizia; Francesco Rocco Pugliese; Maria Pia Ruggieri; Giuseppe Musumeci; Gian Alfonso Cibinel; Francesco Romeo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

9.  Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies.

Authors:  Enrico Cerrato; Matteo Bianco; Akshay Bagai; Leonardo De Luca; Simone Biscaglia; Alessia Luciano; Paola Destefanis; Giorgio Quadri; Ilaria Meynet; Carol Gravinese; Alessandra Chinaglia; Shaun G Goodman; Roberto Pozzi; Gianluca Campo; Ferdinando Varbella
Journal:  Int J Cardiol Heart Vasc       Date:  2018-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.